Study on Exosome Changes in Patients With Proliferative Diabetic Retinopathy
NCT ID: NCT06198543
Last Updated: 2024-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2024-01-31
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
At present, it is known that the pathogenesis of DR is related to hypoxia, oxidative stress, inflammation, abnormal expression of cytokines and gene methylation, but the specific pathogenesis has not been fully clarified. Due to the hidden early symptoms of DR, the lack of basic screening conditions in primary medical and health institutions, and the lack of awareness of DR by patients themselves, many DR patients have already appeared serious retinopathy when they seek medical treatment, resulting in irreversible visual function impairment. In addition, the current clinical treatment methods for DR mainly include retinal photocoagulation therapy, intraocular anti-VEGF drug injection and vitrectomy surgery, etc. These methods are aimed at relatively severe diabetic retinopathy, and there is no effective treatment method for early diabetic retinopathy that can prevent or slow down the occurrence and development of DR. Therefore, to further explore the pathogenesis of DR and develop new therapeutic methods has become an urgent problem.
Exosomes are extracellular vesicles secreted by living cells with a diameter of 40-150nm. With a bilayer lipid membrane structure, exosomes contain a variety of biomolecules such as lipids, proteins, nucleic acids, cytokines, and autoantigens, and are important mediators for the transmission of biological information between cells. Almost all cells can secrete exosomes, and exosomes from different cells have different functions. Exosomes transfer their contents to nearby or distant cells and participate in cell growth, angiogenesis, immune regulation and other processes. Previous studies have shown that exosomes secreted by various cells in the retina are present in the vitreous and aqueous humor of patients and play an important role in the pathogenesis of DR. At the same time, exosomes in the systemic circulation of diabetic patients can also reach the retina through the blood circulation, participate in the initiation process of DR And play an important role. At the same time, due to the double-layer lipid membrane structure, exosomes can also target the coated components to specific cells and tissues through biological barriers such as blood-brain and blood-eye, which is expected to become a highly efficient drug delivery route. Therefore, the role of exosomes in DR Treatment has also attracted much attention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proteomic Study of Plasma Exosomes in Patients With Diabetic Retinopathy
NCT06188013
The Diabetic Retinopathy Screening, Prevention and Control Program
NCT04240652
Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)
NCT03264976
Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy
NCT02307110
Biomarkers of Diabetic Retinopathy Progression
NCT01607190
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. compared the changes of exosomes in intraocular fluid and blood of patients with proliferative diabetic retinopathy and non-diabetic patients.
2. analysed differentially expressed proteins in the exosomes of the two groups of patients using proteomic techniques, laying the foundation for screening possible biomarkers and potential therapeutic targets for the early diagnosis of diabetic retinopathy.
二、Design
1. Subject Population Patients with proliferative diabetic retinopathy and non-diabetic macular epiretinal membrane/macular hole requiring vitrectomy were admitted to the Ophthalmology Department of Xuanwu Hospital, Capital Medical University.
2. Sample Size A total of 60 patients were included in the study.
3. Grouping of Subjects Experimental group: proliferative diabetic retinopathy; Control group: patients with macular epiretinal membranes and macular holes without diabetes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental group
proliferative diabetic retinopathy
No interventions assigned to this group
control group
patients with macular epiretinal membranes and macular holes without diabetes.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients diagnosed with PDR by FFA and requiring vitrectomy for treatment;
3. Patients with no history of diabetes and diagnosed with macular anterior membrane or macular hiatus by color fundus photography and OCT;
4. Sign the informed consent form.
Exclusion Criteria
2. Patients with retinal arteriovenous obstruction;
3. Intraocular infection;
4. Patients with uveitis;
5. In patients with high myopia, the equivalent spherical lens was \> -9.0D;
6. Recent history of cerebral infarction, myocardial infarction and other thrombus;
7. Patients with contraindications to surgery.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
wuhang
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.